about
Inactivation of Zika virus in plasma with amotosalen and ultraviolet A illuminationSeroprevalence of arboviruses among blood donors in French Polynesia, 2011–2013Chikungunya outbreak, French Polynesia, 2014Molecular detection of Zika virus in blood and RNA load determination during the French Polynesian outbreakZika Virus Seroprevalence, French Polynesia, 2014–2015Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell componentsNew evidence for endemic circulation of Ross River Virus in the Pacific Islands and the potential for emergencePrevention of transfusion-transmitted Zika virus in French Polynesia, nucleic acid testing versus pathogen inactivationReal-Time Assessment of Health-Care Requirements During the Zika Virus Epidemic in MartiniqueRecent emergence of dengue virus serotype 4 in French Polynesia results from multiple introductions from other South Pacific Islands.Inactivation of Zika virus in platelet components using amotosalen and ultraviolet A illumination.Use of serum and blood samples on filter paper to improve the surveillance of Dengue in Pacific Island Countries.Epidemiological and molecular features of dengue virus type-1 in New Caledonia, South Pacific, 2001-2013.High risk of dengue type 2 outbreak in French Polynesia, 2017.Silent Circulation of Ross River Virus in French Polynesia.Ross River Virus Seroprevalence, French Polynesia, 2014-2015.Pathogen inactivation of Dengue virus in red blood cells using amustaline and glutathione.Zika virus: new emergencies, potential for severe complications, and prevention of transfusion-transmitted Zika fever in the context of co-circulation of arboviruses.Revising rates of asymptomatic Zika virus infections based on sentinel surveillance data from French Overseas Territories.Amustaline (S-303) treatment inactivates high levels of Chikungunya virus in red-blood-cell components.Zika virus evolution on the edges of the Pacific ocean.Seroprevalence of Dengue and Chikungunya Virus Antibodies, French Polynesia, 2014-2015.Method for simple and rapid concentration of Zika virus particles from infected cell-culture supernatants.Epidemiology and genetic evolution of dengue viruses in the French Pacific Territories.Using paired serology and surveillance data to quantify dengue transmission and control during a large outbreak in FijiAzithromycin Inhibits the Replication of Zika VirusUsing paired serology and surveillance data to quantify dengue transmission and control during a large outbreak in FijiReassessing Serosurvey-Based Estimates of the Zika Symptomatic ProportionRoss River Virus Antibody Prevalence, Fiji Islands, 2013-2015Sustained Low-Level Transmission of Zika and Chikungunya Viruses after Emergence in the Fiji IslandsDengue virus serotype 2 (DENV-2) outbreak, French Polynesia, 2019Zika seroprevalence declines and neutralizing antibodies wane in adults following outbreaks in French Polynesia and FijiFirst evidence of concurrent enzootic and endemic transmission of Ross River virus in the absence of marsupial reservoirs in FijiLong-term persistence of monotypic dengue transmission in small size isolated populations, French Polynesia, 1978-2014Low chikungunya virus seroprevalence two years after emergence in Fiji
P50
Q22330681-5D7C882B-E9EC-4507-87B6-A584AE542B0CQ22330693-F20659F7-557F-4CC8-B6AE-A76B339CA596Q24273378-A55F3037-2238-4CC4-BC9D-CDD4ED52DA09Q27869771-331166BD-69AB-48AD-A21C-459361741B41Q28310404-446E3980-6BAF-46EA-8DFA-D4E4683FA674Q28729789-0B7B4AB1-F1E9-499E-964B-658D8B171645Q28733364-9E7A7816-3FF4-4A8A-BFE9-9D44CCA3EB1CQ28733459-AAD306E4-C33A-408E-87C9-0419721BB5F9Q28804115-C71A6CE3-3AEF-40D2-B450-624A1B2F72FFQ34117709-3CF67046-5CB7-446C-AB52-C928A9C9D24CQ38158233-62CC6868-AA9D-4BC9-854C-C836C0812E2EQ38883588-9D4DAA1D-5F5D-41B9-B160-263278DED55DQ38935048-11CFC8EF-5584-48E4-B1E8-72BE4F10ED65Q40060521-13AD65ED-1EA4-48E1-9E05-C3BC74C9E38DQ41153103-00BB1F02-DE34-4012-B5CC-30A09D7B8B8BQ41933968-79639A00-2DC0-4FB9-9ABA-47EF55725DD6Q41935541-6834B87B-8DB0-407A-BFC3-261D12E87FE3Q42345341-D6825E28-BD3B-412B-87AC-6FB836250FA3Q43047043-6B61563E-2799-4398-8D94-0FE2E84CD623Q47556754-048A4B98-F750-4719-9621-1F43E366B8FFQ47558568-C3B2EEEE-53A9-427F-9A48-7B3045D23F0DQ49820101-C011AFDA-30CF-4F53-96AC-FE7F7595B766Q51336668-E92044E9-AB86-4D86-A144-53138AE3718DQ53160493-A4FD2B50-18E3-4A8F-B21D-01362A5BEB12Q56417600-5D8068B4-A73F-472D-A883-4CEE69C29486Q56417607-CB607414-5CC1-4C4D-8E6D-58D92EAD42DFQ58388838-F9E924D6-332A-41E1-AB0B-56DB7C3BF83CQ59353568-B5B29C92-FC9F-4E22-BB2E-53D6EACD4640Q63246225-2FCF73E7-B6B2-4195-B210-27E02797A1F8Q66678752-3E09703C-C63D-4288-B762-CB895F605C9BQ66679098-3ACD5F05-7C75-4B9A-89C0-F6C4FF197F70Q84957860-B4FDF39B-41B0-4A40-8AEB-2A11FEF004D3Q89956598-2B26E466-201B-4D9E-83CC-FFF8863EC9BBQ90109587-65719CF8-8367-46A8-BEAA-92AFC4F02374Q91123981-0CEBA06A-916F-4D3A-AB39-931D7D5A1D14
P50
description
virologist
@en
viroloog
@nl
name
Maite Aubry
@ast
Maite Aubry
@en
Maite Aubry
@es
Maite Aubry
@nl
type
label
Maite Aubry
@ast
Maite Aubry
@en
Maite Aubry
@es
Maite Aubry
@nl
prefLabel
Maite Aubry
@ast
Maite Aubry
@en
Maite Aubry
@es
Maite Aubry
@nl
P106
P1153
54794896400
P21
P31
P496
0000-0002-9913-5794
P569
2000-01-01T00:00:00Z